依诺肝素钠导致肝功能异常的表现及其危险因素的 Logistic 回归分析.

OBJECTIVE: To probe into the abnormal manifestations of liver function induced by enoxaparin sodium and its influencing factors. METHODS: Medical records of patients who used enoxaparin sodium in the respiratory ward of China-Japan Friendship Hospital from 2021 to 2022 were collected through the hospital information system. According to Roussel Uclaf causality evaluation method 2015 edition, patients whose evaluation results were “extremely likely”, “highly likely” and “ likely” were selected for analysis. RESULTS: A total of 506 patients were enrolled, including 292 males and 214 females. There were 217 cases of high dose (100 AXaIU/ kg, q12 h) enoxaparin sodium and 289 cases of low dose (2 000 / 4 000 AXaIU, qd). Totally 38 patients (7. 5%) developed abnormal liver indexes induced by enoxaparin sodium ( the results of causality evaluation were “ highly likely” and above), the clinical manifestations were mainly elevated transaminase, with normal bilirubin. Binary logistic regression analysis showed that the incidence of abnormal liver function in the high dose group (31 cases) was higher than that in the low dose group (7 cases), the difference was statistically significant (P<0. 001). The incidence of abnormal liver function in males (29 cases) was higher than that in females (9 cases), the difference was statistically significant (P = 0. 023). There was no significant difference in age, smoking history, drinking history and duration of drug use (P>0. 05). Good outcomes can be obtained by discontinuation and replacement of non-heparin anticoagulants. CONCLUSIONS: Abnormal liver function induced by enoxaparin sodium is a reversible adverse reaction with initial remission of symptoms, mainly manifested by elevated aminotransferase, which can be cured after replacement of non-heparin drugs. High dose enoxaparin and male patients are high risk factors for abnormal liver function, and it is necessary to strengthen the drug monitoring of during clinical use of enoxaparin. [ABSTRACT FROM AUTHOR]